Regeneron Pharmaceuticals, Inc.
Corporate Headquarters
777 Old Saw Mill River Road
Tarrytown
New York
10591
United States
Tel: 914-847-7000
Website: https://www.regeneron.com/
About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
Stock Symbol: REGN
Stock Exchange: NASDAQ
Every day, we use our homegrown technologies to discover, develop, research and deliver new medicines that help people with serious diseases. Watch to see what drives us.
Learn more about how our team produces the highest-quality treatments for patients at https://www.regeneron.com/.
1399 articles about Regeneron Pharmaceuticals, Inc.
-
Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio
11/30/2023
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and simultaneous webcast to provide an update on the company's hematology portfolio on Thursday, December 14, 2023 at 8:30 AM ET.
-
Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
11/27/2023
The second Dupixent® investigational Phase 3 chronic obstructive pulmonary disease trial has shown that Dupixent significantly reduced exacerbations, confirming positive published results from the landmark Phase 3 BOREAS trial.
-
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
11/27/2023
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the second Dupixent® investigational Phase 3 chronic obstructive pulmonary disease trial showed that Dupixent significantly reduced exacerbations, confirming positive results from the landmark Phase 3 BOREAS trial.
-
Regeneron Announces Investor Conference Presentation - November 15, 2023
11/15/2023
Regeneron Pharmaceuticals, Inc. will webcast management participation.
-
While Regeneron Pharmaceuticals reported better-than-expected third-quarter results, sales of the company’s lead drug Eylea declined amid increased competition.
-
Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH
11/3/2023
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data from its hematology pipeline will be shared in 19 abstracts at the American Society of Hematology (ASH) Annual Meeting from December 9 to 12 in San Diego, CA.
-
Regeneron Reports Third Quarter 2023 Financial and Operating Results
11/2/2023
Regeneron Pharmaceuticals, Inc. announced financial results for the third quarter of 2023 and provided a business update.
-
EYLEA® HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema
11/1/2023
Regeneron Pharmaceuticals, Inc. announced long-term outcomes and new analyses of pivotal clinical data for EYLEA® HD Injection 8 mg will be presented at the American Academy of Ophthalmology annual meeting in San Francisco from November 3 to 6.
-
Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss
10/26/2023
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced preliminary, positive safety and efficacy results from the first patient (<2 years of age) dosed in the Phase 1/2 CHORD trial investigating otoferlin gene therapy (DB-OTO) in children with profound genetic hearing loss due to mutations of the otoferlin gene.
-
Regeneron Announces Investor Conference Presentations - October 25, 2023
10/25/2023
Regeneron Pharmaceuticals, Inc. will webcast management participation as follows.
-
Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)
10/22/2023
Positive results from a Phase 3 trial demonstrated the efficacy and safety profile of Dupixent® for up to one year in children aged 1 to 11 years with eosinophilic esophagitis was consistent.
-
Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)
10/22/2023
Regeneron Pharmaceuticals, Inc. and Sanofi announced that positive results from a Phase 3 trial evaluating the investigational use of Dupixent® showed consistent efficacy and safety for up to one year in children aged 1 to 11 years with eosinophilic esophagitis.
-
Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)
10/21/2023
Regeneron Pharmaceuticals, Inc. announced the first presentation of key secondary endpoints for an investigational regimen of PD-1 inhibitor Libtayo® as a neoadjuvant monotherapy in stage II to IV resectable cutaneous squamous cell carcinoma.
-
Regeneron and Sanofi Provide Update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
10/20/2023
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in chronic spontaneous urticaria (CSU).
-
Regeneron builds on Together for CHANGE™ initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN
10/18/2023
Regeneron Pharmaceuticals, Inc. announced a five-year, $5 million strategic investment to bolster Nashville, Tennessee’s science, technology, engineering and mathematics ecosystem through high-quality, equitable engagement programs for students and science teachers.
-
The FDA is gearing up for six decisions in the next two weeks, two of which involve highly anticipated medicines for rare diseases.
-
Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO
10/15/2023
Regeneron Pharmaceuticals, Inc. announced the latest clinical data in early- and late-stage cancers from its oncology pipeline will be presented at the European Society for Medical Oncology Congress 2023 from October 20 to 24 in Madrid, Spain.
-
EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA
10/5/2023
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of positive two-year (96 weeks) results from the pivotal PULSAR trial investigating EYLEA® HD (aflibercept) Injection 8 mg with 12- and 16-week dosing regimens, compared to EYLEA® (aflibercept) Injection, in patients with wet age-related macular degeneration (wAMD).
-
The companies are expanding their long-standing CRISPR/Cas9 gene editing collaboration for the second time, now seeking to target neurological and muscular conditions.
-
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
10/3/2023
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Intellia Therapeutics, Inc. (NASDAQ:NTLA) today announced an expanded research collaboration to develop additional in vivo CRISPR-based gene editing therapies focused on neurological and muscular diseases.